COVID-19 Update:Learn more about how we are protecting our patients, families and staff, as well as other important facts about COVID-19.
Birte Wistinghausen, MD
-
Fellowship, Hematology & Oncology, 2001
New York University School of Medicine
-
Residency, Pediatrics, 1999
New York University School of Medicine
-
Internship, Pediatrics, 1997
New York University School of Medicine
-
MD, 1993
Christian-Albrechts Universitaet Zu Kiel
-
- American Board of Pediatrics/Hematology-Oncology
National Provider ID: 1043314784
Birte Wistinghausen, M.D., is a pediatric oncologist and member of the leukemia and lymphoma team. She treats children, adolescents and young adults with non-Hodgkin lymphoma (NHL), histiocytosis and leukemia. Her clinical research concentrates on non-Hodgkin lymphoma, specifically on the role of Epstein-Barr virus (EBV) in Post-Transplant Lymphoproliferative Syndrome (PTLD) and cellular therapy in EBV-positive PTLD as well as the biology and treatment of B-lymphoblastic lymphoma.
Dr. Wistinghausen's roles within the Children’s Oncology Group (COG) include serving as the principal co-investigator of a clinical study using EBV-specific T-cells in patients with post-transplant lymphoproliferative disease and being the responsible investigator for B-lymphoblastic lymphoma. She is also serving as vice-chair for education of the COG NHL committee.